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Abstract 
Purpose: To estimate the therapeutic potential of PD-L1 inhibition in breast cancer, we evaluated the prevalence and 
significance of PD-L1 protein expression with a validated antibody and CD274 gene alternation in a large cohort of 
triple negative breast cancer (TNBC) and correlated with clinicopathological data and patients overall survival.
Methods: Immunohistochemistry and in situ mRNA hybridization was used to detect PD-L1 protein and mRNA 
expression in tumor tissues from 183 TNBC patients respectively. Fluorescence in situ hybridization analysis was per-
formed on PD-L1 strong expression samples to assess copy number on chromosome 9p24.1 of CD274 gene.
Results: Expression of PD-L1 by immune cells was observed in 4.9 % of TNBC, while expression by tumor cells 
accounted for 8.7 %. There was a high concordance in PD-L1 protein expression and PDL1 mRNA expression. Samples 
with PD-L1 strong expression were found to have a CD274 gene copy number gain. PD-L1 expression was correlated 
with higher tumor grade, but was independent of menopausal status, lymph nodes metastasis, histological subtype 
and tumor size. In addition, we used precise stratification of PD-L1 expression on tumor or immune cells of certain 
breast cancer subtype and suggested that patients with PD-L1 expression in basal-like tumors by immune cells or 
with CD274 gene copy number gain had a longer disease-specific overall survival.
Conclusions: Our findings may promote the more precise analysis of PD-L1 expression in breast cancer and aid the 
selection of patients who may benefit from immune therapy.
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Background
Immune responses are fine-tune regulated through a 
combination of stimulatory and inhibitory molecules and 
signal pathways (Dunn et al. 2002). To generate efficient 
antitumor immune responses by cytotoxic T lympho-
cytes (CTLs), inhibition of negative immune checkpoint 
proteins such as cytotoxic T-lymphocyte-associated pro-
tein (CTLA4), programmed cell death 1 (PD-1) and pro-
grammed death ligand 1 (PD-L1) are applied in recent 
clinical studies and trails (Brahmer et al. 2012; Topalian 
et al. 2012; Herbst et al. 2014). PD-L1, which belongs to 
B7 family, binds PD-1 and CD80 as counter receptors 
to offer negative signals that control and suppress CTL 
responses in both autoimmune responses and evasion 
of tumor immunity (Dong et al. 1999; Butte et al. 2007). 
PD-L1 is often expressed by activated immune cells 
including T cells, B cells, myeloid dendritic cells (DCs), 
macrophages and myeloid-derived suppressor cells. In 
addition, PD-L1 has also been found to be expressed in 
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tumor cells and tumor-infiltrating immune cells (Taube 
et al. 2012). Consequently, clinical trials of blocking mon-
oclonal antibodies (mAbs) against PD-1 and PD-L1 in a 
variety of solid tumors show promising results and vali-
date this pathway as a therapeutic target.
Triple-negative breast cancers (TNBC) are defined 
as tumors that lack estrogen receptor (ER), progester-
one receptor (PR), or human epidermal growth factor 
receptor (HER2) expression. These tumors account for 
10–20  % of all breast cancers and are often associated 
with lymphocytic infiltration, higher grade and are bio-
logically more aggressive (Badve et  al. 2011). Despite 
having higher rates of clinical response to chemotherapy, 
TNBC patients have a worse prognosis owing to limited 
treatment options and higher rate of distant recurrence 
(Haffty et al. 2006; Dent et al. 2007). TNBC can be further 
subdivided into basal-like breast cancer and non-basal-
like breast cancer according to immunohistochemical 
marker panels (Gazinska et  al. 2013). Previous studies 
have demonstrated that PD-L1 protein or PDL1 mRNA 
is rarely expressed in breast tumors, relatively enriched 
in basal-like breast tumors (Ali et al. 2015; Sabatier et al. 
2015; Soliman et  al. 2014). However, there is still not a 
unanimous agreement on whether PD-L1 expression in 
immune cells or tumor cells is an independent negative 
prognostic factor in breast cancer.
Here, we analyzed PD-L1 protein expression with a 
validated antibody and in situ PDL1 mRNA expression in 
183 TNBC of Chinese female patients. We investigated 
the prevalence of PD-L1 expression in TNBC and corre-
lated with clinicopathological data and patients survival.
Methods
Patient population
Clinicopathologic information of TNBC patients were 
retrospectively collected from the Department of Pathol-
ogy, Cancer Hospital, Peking Union Medical College, 
Chinese Academy of Medical Sciences, Beijing, China. 
The study comprised women diagnosed with TNBC from 
January 1999 to December 2008. Basal-like breast can-
cer is defined as triple-negative tumors (lack of ER, PR 
and HER2 expression) with expression of cytokeratin 56 
(CK56) and/or epidermal growth factor receptor (EGFR) 
as previously reported. The inclusion criteria were also 
determined as follows: primary operable breast cancer, 
no family history for breast or ovary cancer, no prior 
treatments before surgery, mastectomies, or lumpecto-
mies specimens with sufficient tissue. Tissue microar-
rays (TMAs) were built as previously reported (Zhu et al. 
2015). In brief, two tumor cores and one normal core of 
1.0  mm diameter were taken from each case based on 
hematoxylin and eosin (H&E) staining. Then, TMAs were 
performed with immunohistochemistry (IHC), in  situ 
mRNA hybridization and fluorescence in  situ hybridi-
zation (FISH). The study was approved by the Institute 
Review Board of the Cancer Hospital, Chinese Acad-
emy of Medical Sciences. The methods were carried out 
in accordance with the approved guidelines. Each par-
ticipant signed an Institutional Review Board approved 
informed consent in accordance with current guidelines.
PD‑L1 immunohistochemistry and scoring
A previous validated rabbit monoclonal antibody (clone 
SP142; Ventana, Tucson, AZ) was used in IHC on an 
automated staining platform (Benchmark; Ventana) 
using a concentration of 4.3 µg/ml. Tumor samples were 
represented by double 1.0-mm cores in TMAs. Stained 
slides were scanned using an Aperio Scanscope AT digi-
tal slide scanner. PD-L1 was scored as reported in previ-
ous studies (Haffty et al. 2006), where tumor and immune 
cells were attributed separate scores on a four-point scale 
as follows: 0 (no staining), 1+ (cytoplasmic and/or weak 
membranous staining in <10 % of the positive cells), 2+ 
(weak to moderate cytoplasmic and/or membranous 
staining in ≥10  % of the positive cells) or 3+ (strong 
cytoplasmic and/or membranous staining in ≥10  % of 
the positive cells). PD-L1 scores in patients with multiple 
specimens were based on the highest score.
In situ mRNA hybridization
In situ detection of PD-L1 transcripts in TMA sam-
ples was performed using the RNAscope 2.0 High Def-
inition-BROWN assay with in  situ hybridization probes 
(Advanced Cell Diagnostics, Hayward, CA) as previous 
reported. Briefly, 5  μm sections were deparaffinized, 
boiled with preamplification reagent for 15 min, and sub-
mitted to protease digestion followed by hybridization 
for 7 h with target probes to human PDL1 mRNA. Diam-
inobenzidine (DAB) staining was used to visualize signals 
in a bright field microscope. Stained slides were scanned 
using an Aperio Scanscope AT digital slide scanner.
Fluorescence in situ hybridization
FISH analysis was performed on TMAs to assess copy 
number on chromosome 9p24.1 using the ZytoLight® 
SPEC CD274 (PD-L1)/CEN 9 Dual Color Probe. Dual 
Color Probe is a mixture of a green fluorochrome direct 
labeled SPEC CD274 probe specific for the CD274 genes 
at 9p24.1 and an orange fluorochrome direct labeled CEN 
9 probe specific for the classical satellite III region of 
chromosome 9 (D9Z3) at 9q12. The CD274 FISH results 
were analyzed according to the previous study (Ansell 
et al. 2015). Control probe ratio of at least 3:1 were clas-
sified as amplified, those with a probe ratio of more than 
1:1 but less than 3:1 were classified as relative copy gain, 
and those with a probe ratio of 1:1 but with more than 
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two copies of each probe were classified as polysomic for 
chromosome 9p. Slides were evaluated independently by 
two experts blind to the patient’s history and histological 
findings.
Statistical analysis
Correlations between continuous and ordinal vari-
ables were assessed using Spearman’s rank correlation 
coefficient. Differences of patient characteristics and 
clinicopathologic factors in the two-dimensional cross-
comparison were evaluated statistically by Pearson’s 
χ2 test or Fischer’s exact test. Statistical tests were two-
sided, and P < 0.05 were considered significant. Specific 
overall survival (OS) was calculated from the date of 
diagnosis to the date of death from breast cancer. Follow-
up was measured from the date of diagnosis to the date 
of last news for event-free patients. Survivals were calcu-
lated using the Kaplan–Meier method and curves were 
compared with the log-rank test. Statistics were carried 




PD-L1 expression was measured by IHC and in  situ 
mRNA hybridization (Fig.  1). There was a high con-
cordance in PD-L1 protein expression and PDL1 mRNA 
expression. In addition, seven samples with PD-L1 strong 
expression (score as 3+) were found to have a CD274 
gene copy number gain by detection of FISH (Fig.  2). 
Expression of PD-L1 in tumor and/or immune cells was 
observed in 13.7  % (25/183) TNBC tumors, where 16 
tumors demonstrated basal-like breast phenotype. How-
ever, there was no significant difference in the proportion 
of PD-L1 expressed tumors between basal-like (n = 116) 
and non basal-like (n = 67) breast cancer subtype (13.8 vs 
13.4 %, P = 0.94). Expression of PD-L1 by immune cells 
was observed in 4.9 % (9/183) of TNBC, while expression 
by tumor cells accounted for 8.7  % (16/183). Basal-like 
breast tumors showed 10.4  % (12/116) PD-L1 positive 
tumors cells, while 3.4  % (4/116) with PD-L1 positive 
immune cells.
Clinicopathologic characteristics of PD‑L1 positive TNBC
The clinicopathologic characteristics of TNBC stratified 
by PD-L1 expression was summarized in Table 1. Patients 
with PD-L1 expression demonstrated a slightly younger 
age than those with PD-L1 no expression, although this 
was not nominally statistically significant (64.0 vs 44.3 %, 
P  =  0.09). Tumors with PD-L1 expression were more 
observed with higher tumor grade (G3) than PD-L1 no 
expression groups (96.0 vs 53.8 %, P < 0.0001). In addi-
tion, there was no significantly difference in aspects of 
menopausal status, lymph nodes metastasis, histological 
subtype and tumor size.
Association with overall survival
We assessed the prognostic value of PD-L1 expression in 
terms of OS. Overall survival data were available for 183 
patients with a median follow up of 76.4 months (median 
OS not reached). The 5-year OS was 83.2  % (95  % CI 
0.81–0.85). Expression of PD-L1, by either immune cells 
or tumor cells, was not significantly associated with 
outcome in neither TNBC, basal-like nor non basal-
like groups. However, in basal-like tumors, a subgroup 
with PD-L1 expression by immune cells seemed likely 
to be associated with reduced disease-specific mortality 
although this was not statistically significant (P =  0.30, 
log-rank test, Fig.  3a). In addition, a trend of reduced 
mortality was also noted for TNBC patients with CD274 
gene copy number gain (P = 0.19, log-rank test, Fig. 3b).
Discussion
We investigated the prevalence and pathologic charac-
teristics of PD-L1 expression in a large cohort of TNBC 
breast cancer. Expression of PD-L1 by immune cells was 
observed in 4.9  % of TNBC, while expression by tumor 
cells accounted for 8.7  %. PD-L1 expression was corre-
lated with higher tumor grade of TNBC, but was inde-
pendent of menopausal status, lymph nodes metastasis, 
histological subtype and tumor size. Samples with PD-L1 
strong expression were found to have a CD274 gene copy 
number gain. In addition, there was a trend of longer 
disease-specific overall survival in basal-like tumors with 
PD-L1 expression by immune cells and TNBC patients 
with CD274 gene copy number gain.
This is the first large cohort analysis of PD-L1 protein, 
in  situ mRNA expression and CD274 gene amplifica-
tion in TNBC breast cancer. PD-L1 expression in breast 
cancer was reported in recent studies, however, the 
results varied regarding its expression rate and prognos-
tic value (Ali et  al. 2015; Sabatier et  al. 2015; Qin et  al. 
2015; Schalper et al. 2014). In a study of 870 breast can-
cer patients, PD-L1 expression was observed in more 
than 20 % breast cancer and patients with TNBC seemed 
to have a higher proportion of positive PD-L1 expres-
sion rate of 55.9  % compared with other types (Qin 
et  al. 2015). A previous study of 105 TNBC breast can-
cer revealed that 19 % (20/105) tumors exhibited PD-L1 
expression (Mittendorf et  al. 2014). In addition, Ali, 
et al. found that basal-like breast tumor, which is a sub-
type of TNBC, showed 19 % (56/302) PD-L1 expression 
in >1 % immune cells (Ali et al. 2015). These divergences 
could partially be attributed to the different antibodies 
used, notably in terms of specificity and reproducibility, 
and the IHC scoring system. Here, we used a validated 
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Fig. 1 PD-L1 immunohistochemical and in situ mRNA expression in TNBC tissues. a PD-L1 negative expression with IHC detection (×200), b PD-L1 
negative expression with in situ mRNA hybridization (×200). c Expression of PD-L1 protein in tumor cells (score as 3+) (×200). d In situ mRNA 
expression of PD-L1 is indicated by brown staining in tumor cells (×200). e Expression of PD-L1 protein in immune cells (score as 3+) (×200).  
f In situ mRNA hybridization of PD-L1 is indicated by brown staining in immune cells (×200)
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PD-L1 rabbit monoclonal antibody of clone SP142 and a 
four-point IHC score scale which was proved to be effec-
tive in the previous studies (Herbst et al. 2014; Ali et al. 
2015). We report that expression of PD-L1 by immune 
cells was observed in 4.9  % of TNBC, while expres-
sion by tumor cells accounted for 8.7  %. And basal-like 
Fig. 2 Immunohistochemical (IHC), in situ mRNA and fluorescence in situ hybridization (FISH) analyses of PD-L1 protein expression and CD274 
gene in patients with triple-negative breast cancer (TNBC). a Expression of PD-L1 protein in both immune and tumor cells (score as 3+) (×200);  
b In situ mRNA hybridization of PD-L1 from the same patient is indicated by brown staining (×200); c Representative image obtained from the 
same patient shows a copy number gain in CD274 gene, with CD274 (green) and CEN9 (red) on chromosome 9p24.1 (×1000)
Table 1 Clinicopathologic characteristics and PD-L1 protein expression status
LNM lymph nodes metastasis, NOS not otherwise specified, ILC invasive lobular carcinoma, SD standard deviation
† Two-sided Kruskal–Wallis test
‡ Two-sided χ2 test with continuity correction
§ Fischer’s exact test
Others are two-sided χ2 test
Characterics PD‑L1 expression (n = 25) PD‑L1 no expression (n = 158) P value
Age (years, median) 0.06
 <50 16 (64.0 %) 70 (44.3 %)
 ≥50 9 (36.0 %) 88 (55.7 %)
Menopausal status 0.57‡
 Pre-menopausal 22 (88.0 %) 132 (83.5 %)
 Post-menopausal 3 (12.0 %) 26 (16.5 %)
LNM 0.83
 Present 8 (32.0 %) 54 (34.2 %)
 Absent 17 (68.0 %) 104 (65.8 %)
Tumor grade <0.0001§
 G1 0 (0 %) 3 (1.9 %)
 G2 1 (4.0 %) 70 (44.3 %)
 G3 24 (96.0 %) 85 (53.8 %)
Tumor type 0.25§
 Ductal NOS 21 (84.0 %) 146 (92.4 %)
 ILC 0 (0 %) 1 (0.6 %)
 Other 4 (16.0 %) 11 (7.0 %)
Basal-like subtype 0.94
 Yes 16 (64.0 %) 100 (63.3 %)
 No 9 (36.0 %) 58 (36.7 %)
Tumor embolus 0.32‡
 Yes 1 (4.0 %) 21 (13.3 %)
 No 24 (96.0 %) 137 (86.7 %)
Tumor size 0.06†
 Mean (SD) 2.28 ± 0.91 2.74 ± 1.13
 Median 2.20 2.5
 Range 0.70–4.30 0.80–8.0
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breast tumors showed a total of 13.8  % PD-L1 expres-
sion either by immune cells or tumor cells. This was in 
accordance with two previous studies that less 20  % 
basal-like breast tumors exhibited PD-L1 expression (Ali 
et al. 2015; Mittendorf et al. 2014). In addition, previous 
observations also indicated that basal breast cancer cells 
constitutively express the high levels of PD-L1. Amplifi-
cation of CD274 has been observed in the setting of EBV-
positive gastric cancer (Cancer Genome Atlas Research 
Network 2014) and in samples of Hodgkin’s lymphoma 
from patients who have had a clinical response to PD-1 
inhibition (Ansell et al. 2015). Our results indicated that 
CD274 gene was only slightly amplified in a small subset 
of breast cancer which showed strong protein expression 
of PD-L1.
Another focus of PD-L1 expression in breast can-
cer was notably on its prognostic value. A high expres-
sion of PD-L1 on tumor cells was associated with poor 
prognosis in several human maglignancies, such as non 
small-cell non cancer (NSCLC), melanoma and renal 
cancer (Azuma et  al. 2014; Ott et  al. 2013; Thomp-
son et  al. 2007). Especially, in a very recently published 
paper, Tao Qin’s work have revealed that patients with 
positive PD-L1 expression had significantly decreased 
survival compared to those with PD-L1 negative expres-
sion regardless of breast cancer subtype (Qin et al. 2015). 
However, other studies have opposite conclusions that 
PD-L1 protein or mRNA expression was associated with 
improved survival notably with basal-like breast tumors 
(Ali et  al. 2015; Schalper et  al. 2014). Furthermore, the 
improved survival was only observed in patients with a 
subgroup of basal-like tumors which PD-L1 expression 
was found in immune cells. These results indicated that 
the precise stratification of PD-L1 expression on tumor 
or immune cells of certain breast cancer subtype could 
promote the better understanding of its role on patients’ 
outcome. Our results suggested that in basal-like tumors, 
a subgroup with PD-L1 expression by immune cells 
seemed like to be associated with reduced disease-spe-
cific mortality. In addition, a trend of reduced mortality 
was also noted for TNBC patients with CD274 gene copy 
number gain (P = 0.19) although this did not reach a sig-
nificant difference due to limited sample size.
Patients diagnosed with TNBC have a higher risk of 
disease recurrence in all breast cancer subtypes (Le Du 
et  al. 2015). Thus, identification and evaluation of new 
biomarkers and therapeutic agents is urgent for these 
patients. Because TNBC is a heterogeneous disease, 
the use of genome-wide association study may pro-
vide a rational for prognosis and prediction to therapy 
(Burstein et  al. 2015; Lehmann et  al. 2011; Prat et  al. 
2013). However, the biological classification based on 
gene expression profiles was until now unclear whether 
it could surely guide the targeted therapy. Anti PD-L1/
PD-1 pathway therapy represents a promising cancer 
immune therapy method (Brahmer et  al. 2012). Our 
results in addition with previous studies have strength-
ened the idea that PD-L1 is mainly expressed in TNBC 
of all breast cancer subtype. Through finely stratification 
of PD-L1 expression on TNBC, our observations sug-
gested that PD-L1 inhibitors may also benefit a small 
subset of women with TNBC with tumors that express 
PD-L1.
The main limitation of this study was the use of TMAs 
for representation of tumors. In some tumors, immune 
infiltration may be heterogeneous and this heterogeneity 
Fig. 3 Kaplan–Meier survival curves of overall survival (OS) in patients with TNBC. a Kaplan–Meier graphical analysis of the OS in patients with 
basal-like tumors, a subgroup with PD-L1 expression by immune cells. b Kaplan–Meier graphical analysis of the OS in patients with CD274 gene 
copy number gain
Page 7 of 8Guo et al. SpringerPlus  (2016) 5:805 
will not be captured by TMAs. However, TMAs enable 
the conduct of large-scale pathology studies and in this 
way ultimately lead to more reliable conclusions.
To data, this is the first large study of PD-L1 expression 
in TNBC breast cancer. We found that PD-L1 expres-
sion was correlated with higher tumor grade of TNBC, 
but was independent of menopausal status, lymph nodes 
metastasis, histological subtype and tumor size. Samples 
with PD-L1 strong expression were associated with a 
CD274 gene copy number gain. In addition, we used the 
precise stratification of PD-L1 expression on tumor or 
immune cells of certain breast cancer subtype and sug-
gested that patients with PD-L1 expression in basal-like 
tumors by immune cells had a longer disease-specific 
overall survival. These findings may promote the more 
precise analysis of PD-L1 expression in breast cancer and 
aid the selection of patients who will surely benefit from 
immune therapy.
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